346 related articles for article (PubMed ID: 18662879)
21. In vitro TRPV1 activity of piperine derived amides.
Correa EA; Högestätt ED; Sterner O; Echeverri F; Zygmunt PM
Bioorg Med Chem; 2010 May; 18(9):3299-306. PubMed ID: 20381363
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and structure-activity relationship of simple bis-amides as potent inhibitors of GlyT1.
Jolidon S; Alberati D; Dowle A; Fischer H; Hainzl D; Narquizian R; Norcross R; Pinard E
Bioorg Med Chem Lett; 2008 Oct; 18(20):5533-6. PubMed ID: 18805008
[TBL] [Abstract][Full Text] [Related]
23. Structure-activity studies of a novel series of isoxazole-3-carboxamide derivatives as TRPV1 antagonists.
Palin R; Abernethy L; Ansari N; Cameron K; Clarkson T; Dempster M; Dunn D; Easson AM; Edwards D; Maclean J; Everett K; Feilden H; Ho KK; Kultgen S; Littlewood P; McArthur D; McGregor D; McLuskey H; Neagu I; Neale S; Nisbet LA; Ohlmeyer M; Pham Q; Ratcliffe P; Rong Y; Roughton A; Sammons M; Swanson R; Tracey H; Walker G
Bioorg Med Chem Lett; 2011 Feb; 21(3):892-8. PubMed ID: 21236666
[TBL] [Abstract][Full Text] [Related]
24. Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-dihydro-2H-benzo[1,4]oxazines.
Perry B; Alexander R; Bennett G; Buckley G; Ceska T; Crabbe T; Dale V; Gowers L; Horsley H; James L; Jenkins K; Crépy K; Kulisa C; Lightfoot H; Lock C; Mack S; Morgan T; Nicolas AL; Pitt W; Sabin V; Wright S
Bioorg Med Chem Lett; 2008 Aug; 18(16):4700-4. PubMed ID: 18644721
[TBL] [Abstract][Full Text] [Related]
25. Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides.
Norman MH; Zhu J; Fotsch C; Bo Y; Chen N; Chakrabarti P; Doherty EM; Gavva NR; Nishimura N; Nixey T; Ognyanov VI; Rzasa RM; Stec M; Surapaneni S; Tamir R; Viswanadhan VN; Treanor JJ
J Med Chem; 2007 Jul; 50(15):3497-514. PubMed ID: 17585749
[TBL] [Abstract][Full Text] [Related]
26. 4-Hydroxy-5-pyrrolinone-3-carboxamide HIV-1 integrase inhibitors.
Pace P; Spieser SA; Summa V
Bioorg Med Chem Lett; 2008 Jul; 18(14):3865-9. PubMed ID: 18595690
[TBL] [Abstract][Full Text] [Related]
27. Small, non-peptide C5a receptor antagonists: part 1.
Blagg J; Mowbray C; Pryde DC; Salmon G; Schmid E; Fairman D; Beaumont K
Bioorg Med Chem Lett; 2008 Oct; 18(20):5601-4. PubMed ID: 18809326
[TBL] [Abstract][Full Text] [Related]
28. Identification of a novel class of succinyl-nitrile-based Cathepsin S inhibitors.
Bekkali Y; Thomson DS; Betageri R; Emmanuel MJ; Hao MH; Hickey E; Liu W; Patel U; Ward YD; Young ER; Nelson R; Kukulka A; Brown ML; Crane K; White D; Freeman DM; Labadia ME; Wildeson J; Spero DM
Bioorg Med Chem Lett; 2007 May; 17(9):2465-9. PubMed ID: 17379516
[TBL] [Abstract][Full Text] [Related]
29. M3 muscarinic acetylcholine receptor antagonists: SAR and optimization of bi-aryl amines.
Budzik B; Wang Y; Shi D; Wang F; Xie H; Wan Z; Zhu C; Foley JJ; Nuthulaganti P; Kallal LA; Sarau HM; Morrow DM; Moore ML; Rivero RA; Palovich M; Salmon M; Belmonte KE; Laine DI; Jin J
Bioorg Med Chem Lett; 2009 Mar; 19(6):1686-90. PubMed ID: 19243945
[TBL] [Abstract][Full Text] [Related]
30. Discovery of potent transient receptor potential vanilloid 1 antagonists: design and synthesis of phenoxyacetamide derivatives.
Takahashi E; Hirano N; Nagahara T; Yoshikawa S; Momen S; Yokokawa H; Hayashi R
Bioorg Med Chem Lett; 2013 Jun; 23(11):3154-6. PubMed ID: 23632270
[TBL] [Abstract][Full Text] [Related]
31. Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development.
Rami HK; Thompson M; Stemp G; Fell S; Jerman JC; Stevens AJ; Smart D; Sargent B; Sanderson D; Randall AD; Gunthorpe MJ; Davis JB
Bioorg Med Chem Lett; 2006 Jun; 16(12):3287-91. PubMed ID: 16580202
[TBL] [Abstract][Full Text] [Related]
32. Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate.
Doherty EM; Fotsch C; Bannon AW; Bo Y; Chen N; Dominguez C; Falsey J; Gavva NR; Katon J; Nixey T; Ognyanov VI; Pettus L; Rzasa RM; Stec M; Surapaneni S; Tamir R; Zhu J; Treanor JJ; Norman MH
J Med Chem; 2007 Jul; 50(15):3515-27. PubMed ID: 17585750
[TBL] [Abstract][Full Text] [Related]
33. From arylureas to biarylamides to aminoquinazolines: discovery of a novel, potent TRPV1 antagonist.
Zheng X; Hodgetts KJ; Brielmann H; Hutchison A; Burkamp F; Brian Jones A; Blurton P; Clarkson R; Chandrasekhar J; Bakthavatchalam R; De Lombaert S; Crandall M; Cortright D; Blum CA
Bioorg Med Chem Lett; 2006 Oct; 16(19):5217-21. PubMed ID: 16870426
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and structural optimization of multiple H-bonding region of diarylalkyl (thio)amides as novel TRPV1 antagonists.
Li FN; Kim NJ; Chang DJ; Jang J; Jang H; Jung JW; Min KH; Jeong YS; Kim SY; Park YH; Kim HD; Park HG; Suh YG
Bioorg Med Chem; 2009 Dec; 17(24):8149-60. PubMed ID: 19897373
[TBL] [Abstract][Full Text] [Related]
35. Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N-aryl cinnamides.
Doherty EM; Fotsch C; Bo Y; Chakrabarti PP; Chen N; Gavva N; Han N; Kelly MG; Kincaid J; Klionsky L; Liu Q; Ognyanov VI; Tamir R; Wang X; Zhu J; Norman MH; Treanor JJ
J Med Chem; 2005 Jan; 48(1):71-90. PubMed ID: 15634002
[TBL] [Abstract][Full Text] [Related]
36. Dopamides, vanillylamides, ethanolamides, and arachidonic acid amides of anti-inflammatory and analgesic drug substances as TRPV1 ligands.
Sinning C; Watzer B; De Petrocellis L; Di Marzo V; Imming P
ChemMedChem; 2008 Dec; 3(12):1956-64. PubMed ID: 19003845
[TBL] [Abstract][Full Text] [Related]
37. N-Tetrahydroquinolinyl, N-quinolinyl and N-isoquinolinyl biaryl carboxamides as antagonists of TRPV1.
Westaway SM; Chung YK; Davis JB; Holland V; Jerman JC; Medhurst SJ; Rami HK; Stemp G; Stevens AJ; Thompson M; Winborn KY; Wright J
Bioorg Med Chem Lett; 2006 Sep; 16(17):4533-6. PubMed ID: 16806913
[TBL] [Abstract][Full Text] [Related]
38. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway.
Gunthorpe MJ; Chizh BA
Drug Discov Today; 2009 Jan; 14(1-2):56-67. PubMed ID: 19063991
[TBL] [Abstract][Full Text] [Related]
39. In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists.
Perner RJ; DiDomenico S; Koenig JR; Gomtsyan A; Bayburt EK; Schmidt RG; Drizin I; Zheng GZ; Turner SC; Jinkerson T; Brown BS; Keddy RG; Lukin K; McDonald HA; Honore P; Mikusa J; Marsh KC; Wetter JM; George KS; Jarvis MF; Faltynek CR; Lee CH
J Med Chem; 2007 Jul; 50(15):3651-60. PubMed ID: 17583335
[TBL] [Abstract][Full Text] [Related]
40. The identification and optimisation of novel and selective diamide neuropeptide Y Y2 receptor antagonists.
Lunniss GE; Barnes AA; Barton N; Biagetti M; Bianchi F; Blowers SM; Caberlotto L; Emmons A; Holmes IP; Montanari D; Norris R; Walters DJ; Watson SP
Bioorg Med Chem Lett; 2009 Aug; 19(15):4022-5. PubMed ID: 19581086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
